The United Laboratories International Holdings Limited (3933.HK)
HKD 13.94
(0.29%)
HKD 13.94
(0.29%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.5 Billion CNY | -38.94% |
| 2022 | 2.46 Billion CNY | 33.69% |
| 2021 | 1.84 Billion CNY | -16.7% |
| 2020 | 2.21 Billion CNY | -55.76% |
| 2019 | 4.99 Billion CNY | 17.54% |
| 2018 | 4.25 Billion CNY | -12.45% |
| 2017 | 4.85 Billion CNY | -10.73% |
| 2016 | 5.44 Billion CNY | 2.38% |
| 2015 | 5.31 Billion CNY | -10.41% |
| 2014 | 5.93 Billion CNY | -1.59% |
| 2013 | 6.02 Billion CNY | 14.67% |
| 2012 | 5.25 Billion CNY | 61.18% |
| 2011 | 3.26 Billion CNY | 62.83% |
| 2010 | 2 Billion CNY | 3.15% |
| 2009 | 1.94 Billion CNY | 24.2% |
| 2008 | 1.56 Billion CNY | 21.24% |
| 2007 | 1.28 Billion CNY | -12.26% |
| 2006 | 1.46 Billion CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 2.43 Billion CNY | 0.0% |
| 2023 Q2 | 1.52 Billion CNY | 0.0% |
| 2023 Q4 | 1.5 Billion CNY | 0.0% |
| 2023 FY | 1.5 Billion CNY | -38.94% |
| 2022 Q4 | 2.46 Billion CNY | 0.0% |
| 2022 FY | 2.46 Billion CNY | 33.69% |
| 2022 Q2 | 2.14 Billion CNY | 0.0% |
| 2021 Q2 | 2.24 Billion CNY | 0.0% |
| 2021 FY | 1.84 Billion CNY | -16.7% |
| 2021 Q4 | 1.84 Billion CNY | 0.0% |
| 2020 Q2 | 3.26 Billion CNY | 0.0% |
| 2020 Q4 | 2.21 Billion CNY | 0.0% |
| 2020 FY | 2.21 Billion CNY | -55.76% |
| 2019 Q2 | 4.47 Billion CNY | 0.0% |
| 2019 FY | 4.99 Billion CNY | 17.54% |
| 2019 Q4 | 4.99 Billion CNY | 0.0% |
| 2018 Q2 | 4.88 Billion CNY | 0.0% |
| 2018 Q4 | 4.25 Billion CNY | 0.0% |
| 2018 FY | 4.25 Billion CNY | -12.45% |
| 2017 FY | 4.85 Billion CNY | -10.73% |
| 2017 Q4 | 4.85 Billion CNY | 0.0% |
| 2017 Q2 | 5.59 Billion CNY | 0.0% |
| 2016 Q4 | 5.44 Billion CNY | 0.0% |
| 2016 FY | 5.44 Billion CNY | 2.38% |
| 2016 Q2 | 5.51 Billion CNY | 0.0% |
| 2015 FY | 5.31 Billion CNY | -10.41% |
| 2015 Q2 | 5.61 Billion CNY | 0.0% |
| 2015 Q4 | 5.31 Billion CNY | 0.0% |
| 2014 Q2 | 6.22 Billion CNY | 0.0% |
| 2014 Q4 | 5.93 Billion CNY | 0.0% |
| 2014 FY | 5.93 Billion CNY | -1.59% |
| 2013 Q2 | 6.35 Billion CNY | 0.0% |
| 2013 FY | 6.02 Billion CNY | 14.67% |
| 2013 Q4 | 6.02 Billion CNY | 0.0% |
| 2012 Q2 | 3.71 Billion CNY | 0.0% |
| 2012 Q4 | 5.25 Billion CNY | 0.0% |
| 2012 FY | 5.25 Billion CNY | 61.18% |
| 2011 Q4 | 3.26 Billion CNY | 0.0% |
| 2011 Q2 | 2.56 Billion CNY | 0.0% |
| 2011 FY | 3.26 Billion CNY | 62.83% |
| 2010 Q4 | 2 Billion CNY | 0.0% |
| 2010 FY | 2 Billion CNY | 3.15% |
| 2010 Q2 | 2.32 Billion CNY | 0.0% |
| 2009 Q4 | 1.94 Billion CNY | 0.0% |
| 2009 FY | 1.94 Billion CNY | 24.2% |
| 2008 FY | 1.56 Billion CNY | 21.24% |
| 2007 FY | 1.28 Billion CNY | -12.26% |
| 2006 FY | 1.46 Billion CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 6.8 Million HKD | -21980.532% |
| Grand Pharmaceutical Group Limited | 3.4 Billion HKD | 55.829% |
| Extrawell Pharmaceutical Holdings Limited | 120.41 Million HKD | -1148.803% |
| Wai Yuen Tong Medicine Holdings Limited | 460.94 Million HKD | -226.215% |
| Qianhai Health Holdings Limited | 487 Thousand HKD | -308664.682% |
| Lee's Pharmaceutical Holdings Limited | 204.14 Million HKD | -636.594% |
| Essex Bio-Technology Limited | 294.02 Million HKD | -411.418% |
| Tongfang Kontafarma Holdings Limited | 333.82 Million HKD | -350.443% |
| PuraPharm Corporation Limited | 424.77 Million HKD | -254.0% |
| SSY Group Limited | 3.37 Billion HKD | 55.434% |
| JBM (Healthcare) Limited | 133.4 Million HKD | -1027.14% |
| Jacobson Pharma Corporation Limited | 749.37 Million HKD | -100.657% |
| China Resources Pharmaceutical Group Limited | 85.84 Billion HKD | 98.248% |